TORONTO, Aug. 14, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today reported financial results for the three months ended June 30, 2019, and provided an update on its operations.
Recent Corporate Highlights
“This was a pivotal quarter for Profound, marked by TACT’s compelling clinical trial data, positive TULSA-PRO® and Sonalleve® user feedback from leading researchers and clinicians at our first Analyst & Investor Day event, the strong reception that TULSA-PRO® received at AUA, and the filing of our 510(k) application for TULSA-PRO® with the FDA,” said Arun Menawat, Profound’s CEO.
Summary Second Quarter 2019 Results
All amounts, unless specified otherwise, are expressed in Canadian dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board, applicable to the preparation of interim financial statements, including IAS 34, Interim Financial Reporting.
For the quarter ended June 30, 2019, the Company recorded revenue of $574,109, with $465,840 from the sale of products and $108,269 from installation and training services. While second quarter 2019 revenue increased approximately 169% from $213,343 in the same three-month period a year ago, the Company noted that its Q2-2019 sales levels were negatively impacted by the lag time between product ordering and shipment.
“Despite triple-digit percentage growth over the comparable period in 2018, revenue for the 2019 second quarter was still below our internal expectation. This was due to some unfortunate timing, as a Sonalleve® system order slipped into Q3,” commented Dr. Menawat. “Had this shipment been completed in Q2-2019, revenues would have been approximately $1.2 million. Fortunately, with the recognition of this revenue anticipated in the third quarter, along with our growing sales pipeline of both TULSA-PRO® and Sonalleve® products, we remain very well positioned and expect increasing commercial traction throughout the remainder of 2019.”
The Company recorded a net loss for the three months ended June 30, 2019 of $5,844,134, or $0.05 per common share, compared to a net loss of $5,831,028, or $0.05 per common share, for the three months ended June 30, 2018. The increase in net loss was primarily attributed to an increase in research and development (“R&D”) expenses of $838,446, an increase in selling and distribution expenses of $41,644 and an increase in net finance costs of $30,181. This was offset by a decrease in general and administrative (“G&A”) expenses of $650,206 and an increase in gross profits of $242,959
Expenditures for R&D for the three months ended June 30, 2019 were higher by $838,446 compared to the three months ended June 30, 2018. Clinical trial costs, materials, share based compensation and salaries and benefits increased by $219,569, $294,225, $33,986, and $244,263, respectively. These increases were due to increased spending and testing for R&D and U.S. regulatory projects, analysis of TACT clinical data, options awarded to employees, increased R&D personnel and a $60,000 decrease in investment tax credits because of lower eligibility for refundable tax credits. Offsetting these amounts were decreases in rent of $57,456 due to the adoption of IFRS 16 resulting in the recognition of lower rental costs. Depreciation expenses increased by $26,762 due to the adoption of IFRS 16 with the depreciation of the right-of-use assets.
G&A expenses for the second quarter of 2019 decreased by $650,206 compared to the three months ended June 30, 2018. Salaries and benefits, consulting fees and travel decreased by $386,996, $386,594 and $24,337, respectively due to no bonuses being awarded to management this quarter, lower G&A project initiatives and decreased travel to customer sites. These costs were offset by an increase in share based compensation of $111,817, due to options awarded to various employees. Depreciation expense increased by $59,759 due to the adoption of IFRS 16 with the depreciation of the right-of-use assets.
Liquidity and Outstanding Share Capital
As at June 30, 2019, the Company had cash of $20,493,470.
As at August 14, 2019, Profound had an unlimited number of authorized common shares with 108,072,939 common shares issued and outstanding.
Conference Call Details
Profound Medical is pleased to invite all interested parties to participate in a conference call today, August 14, 2019, at 4:30 pm. ET during which time the results will be discussed.
|Live Call:||1-877-407-9210 (Canada and the United States)|
About Profound Medical Corp.
Profound develops and markets customizable, incision-free therapies for the ablation of diseased tissue.
Profound is commercializing TULSA-PRO®, a novel technology that combines real-time MRI, robotically-driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO® is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while actively protecting the urethra and rectum to help preserve the patient’s natural functional abilities.
TULSA-PRO® is CE marked and commercially launched in key European and other CE mark jurisdictions. TULSA-PRO® is demonstrating to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer, and the transition zone in large volume benign prostatic hyperplasia (BPH).
In April 2019, Profound announced positive topline results from a multicenter, prospective clinical trial, TACT, which is expected to support its recent application to the FDA for 510(k) clearance to market TULSA-PRO® in the United States.
Profound is also commercializing Sonalleve®, an innovative therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases. Sonalleve® has also been approved by the China Food and Drug Administration for the non-invasive treatment of uterine fibroids. The Company is in the early stages of exploring additional potential treatment markets for Sonalleve® where the technology has been shown to have clinical application, such as non-invasive ablation of abdominal cancers and hyperthermia for cancer therapy.
This release includes forward-looking statements regarding Profound and its business which may include, but is not limited to, the expectations regarding the efficacy of Profound’s technology in the treatment of prostate cancer, uterine fibroids and palliative pain treatment. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "is expected", "expects", "scheduled", "intends", "contemplates", "anticipates", "believes", "proposes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Such statements are based on the current expectations of the management of Profound. The forward-looking events and circumstances discussed in this release, may not occur by certain specified dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting the company, including risks regarding the pharmaceutical industry, economic factors, the equity markets generally and risks associated with growth and competition. Although Profound has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Profound undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, other than as required by law.
For further information, please contact:
Profound Medical Corp.
Interim Condensed Consolidated Balance Sheet
|Trade and other receivables||2,934,283||2,686,112|
|Investment tax credits receivable||480,000||480,000|
|Prepaid expenses and deposits||161,685||434,871|
|Total current assets||27,680,784||37,919,789|
|Property and equipment||914,848||1,207,357|
|Accounts payable and accrued liabilities||2,339,451||3,912,350|
|Derivative financial instrument||152,423||98,203|
|Income taxes payable||164,079||297,353|
|Total current liabilities||7,465,677||7,879,360|
|Accumulated other comprehensive loss||(86,935||)||(28,703||)|
|Total Shareholders’ Equity||18,419,527||26,626,334|
|Total Liabilities and Shareholders’ Equity||37,862,711||46,549,872|
Profound Medical Corp.
Interim Condensed Consolidated Statement of Loss and Comprehensive Loss
|Cost of sales||244,066||126,259||777,422||357,334|
|Research and development||3,186,355||2,347,909||5,864,101||4,864,690|
|General and administrative||1,586,323||2,236,529||3,100,436||3,539,733|
|Selling and distribution||1,154,869||1,113,225||625,524||2,060,127|
|Total operating expenses||5,927,547||5,697,663||9,590,061||10,464,550|
|Other income and expense|
|Loss before tax||5,823,934||5,806,828||8,716,820||10,708,614|
|Net loss for the period||5,844,134||5,831,028||8,770,820||10,769,214|
|Other comprehensive loss|
|Item that may be reclassified to profit or loss|
|Foreign currency translation adjustment - net of tax||(11,843||)||57,943||(58,232||)||14,695|
|Net loss and comprehensive loss for the period||5,832,291||5,888,971||8,712,588||10,783,909|
|Loss per share|
|Basic and diluted net loss per share||0.05||0.05||0.08||0.12|
Profound Medical Corp.
Interim Condensed Consolidated Statement of Cash Flows
|Net loss for the period||(8,770,820||)||(10,769,214||)|
|Adjustments to reconcile net loss to net cash flows from operating activities:|
|Depreciation of property and equipment||257,299||284,167|
|Amortization of intangible assets||564,219||564,219|
|Depreciation of right-of-use assets||204,126||-|
|Interest and accretion expense||681,258||522,215|
|Change in deferred rent||-||20,670|
|Change in fair value of derivative financial instrument||54,220||-|
|Change in fair value of contingent consideration||(208,911||)||(24,546||)|
|Changes in non-cash working capital balances|
|Investment tax credits receivable||-||(120,000||)|
|Trade and other receivables||(248,171||)||3,227,089|
|Prepaid expenses and deposits||63,186||(93,660||)|
|Accounts payable and accrued liabilities||(1,612,144||)||(2,320,795||)|
|Income taxes payable||(133,274||)||62,089|
|Net cash flow used in operating activities||(9,504,257||)||(9,135,773||)|
|Issuance of common shares||-||34,500,000|
|Transaction costs paid||-||(2,455,695||)|
|Payment of other liabilities||(16,203||)||(164,389||)|
|Payment of long-term debt and interest||(534,709||)||(1,953,822||)|
|Proceeds from share options exercised||5,399||102,375|
|Payment of lease liabilities||(143,943||)||-|
|Total cash (used in) from financing activities||(689,456||)||30,028,469|
|Net change in cash during the period||(10,193,713||)||20,892,696|
|Cash – Beginning of period||30,687,183||11,103,223|
|Cash – End of period||20,493,470||31,995,919|